Johnson & Johnson (NYSE:JNJ) Position Reduced by Qtron Investments LLC

Qtron Investments LLC reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,062 shares of the company's stock after selling 3,195 shares during the period. Johnson & Johnson makes up 0.5% of Qtron Investments LLC's portfolio, making the stock its 27th largest holding. Qtron Investments LLC's holdings in Johnson & Johnson were worth $3,769,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. IFS Advisors LLC increased its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares during the last quarter. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth about $32,000. Finally, Conquis Financial LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth about $33,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.5 %

Johnson & Johnson stock traded down $0.71 during midday trading on Tuesday, reaching $153.66. The company's stock had a trading volume of 10,721,484 shares, compared to its average volume of 7,975,057. The business has a 50-day simple moving average of $159.38 and a 200-day simple moving average of $155.11. The company has a market cap of $370.29 billion, a P/E ratio of 23.11, a P/E/G ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.38%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on JNJ shares. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 28th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Finally, Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Eight research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $171.50.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.